Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Completion of Golden Eagle Acquisition

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.  FOR IMMEDIATE RELEASE. 22 October 2021 EnQuest PLC Completion of the acquisition of the Golden Eagle Area Development EnQuest PLC ("EnQuest", or the "Company") is pleased to announce that it has completed the acquisition ("Completion") of a 26.69% non-operated

ASETEK PRESENTS THIRD QUARTER 2021 RESULTS ON THURSDAY, 28 OCTOBER

Asetek will release its financial results for the third quarter of 2021 on Thursday, 28 October at 7:00 AM CEST. CEO André Sloth Eriksen and CFO Peter Dam Madsen will present the Company's results at 8:00 AM CEST and invites investors, analysts and media to join the presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed via live webcast or conference call. Webcast - audio and slide presentation:Please join the results webcast via the following link: https://streams.eventcdn.net/asetek/2021q3 Conference call - audio only:Please dial

Cantargia reports treatment of first patient in CESTAFOUR clinical trial

Cantargia AB today announced that the first patient has started treatment with nadunolimab (CAN04) and chemotherapy in the phase I/II clinical trial CESTAFOUR. This trial evaluates CAN04 in combination with standard of care chemotherapy in three different forms of cancer: biliary tract cancer (BTC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) and is planned to include up to a total of 165 patients.The interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN04 is Cantargia’s lead program and is investigated in multiple clinical trials. Approval was recently

RNB Retail and Brands AB meets the listing requirements for Nasdaq First North Growth Market and publishes company description of Coala-Life AB

RNB Retail and Brands AB ("RNB" or "the Company") announces that Nasdaq Stockholm AB has today announced that the Company meets the listing requirements for Nasdaq First North Growth Market. RNB today also publishes the company description prepared in connection with the transaction that RNB published in a press release on 27 September 2021, whereby RNB intends to acquire Coala-Life AB ("Coala Life") through a non-cash issue and further carry out a change of marketplace from Nasdaq Stockholm. to Nasdaq First North Growth Market. Provided that the Extraordinary General Meeting of RNB

DexTech Medical AB Interim report July 1 2021 - September 30, 2021

Summary of the First Quarter (2021-07-01 – 2021-09-30) • Net sales amounted to MSEK 0,0 (0,0) • Operating profit/loss amounted to MSEK -0,9 (-1,5) • Earnings per share* SEK -0,06 (-0.10) • Cash and cash equivalents at the end of the period amounted to MSEK 3,0 (5,5) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 14,920,478. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year. CEO's comment There are significant similarities

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B635TG28 Issuer Name ENQUEST PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Cobas Asset Management, SGIIC, S.A. City of registered office (if applicable) Madrid Country of registered office (if applicable) Spain 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation,

“Quarantine-free” Holiday in Thailand from 1 November 2021

Thailand reopen to fully vaccinated foreign visitors, including returning Thais and foreign residents, from the approved countries to enter the Kingdom by air with no quarantine requirements from 1 November, 2021. Key Points · Fully vaccinated travelers against COVID-19 from 46 nations includingNordic and Baltic to visit Thailand · Travelers must take 2 RT-PCR COVID tests (72 hrs before flight and onarrival day at the hotel), And Antigen self-test kit on day 6-7. · Travelers must stay in SHA Plus hotel at least 1 day while waiting for theresult Who? ·

Invitation to presentation of First Camp Group's report for the third quarter of 2021

First Camp Group AB's report for the third quarter of 2021 will be published on Wednesday, October 27, 2021 at around 08:00.A digital conference will be held at 10:00. At the conference, Johan Söör, CEO and Göran Meijer, CFO, will present the report, followed by a question and answer session. The presentation will be held in English. A presentation and video link to the conference will be available at https://corporate.firstcamp.se/en/for-investors from the time the report for the third quarter of 2021 is published.

Invitation to presentation of First Camp Group's report for the third quarter of 2021

First Camp Group AB's report for the third quarter of 2021 will be published on Wednesday, October 27, 2021 at around 08:00.A digital conference will be held at 10:00. At the conference, Johan Söör, CEO and Göran Meijer, CFO, will present the report, followed by a question and answer session. The presentation will be held in English. A presentation and video link to the conference will be available at https://corporate.firstcamp.se/en/for-investors from the time the report for the third quarter of 2021 is published.

Oncopeptides withdraws Pepaxto®[ ]in US, scale down organization and focus on R&D

STOCKHOLM — October 22, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the company has decided to withdraw Pepaxto[® ](INN melphalan flufenamide) from the market in the US, following the phase 3 OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA. Pepaxto was granted accelerated approval on February 26[th] 2021.

Latest innovations in RayStation, RayCare and RayIntelligence to be presented at ASTRO 2021

RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ASTRO 2021 , to be held in Chicago, October 24-27. Attendees will be able to book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and RayIntelligence®, the new cloud-based analytics system for oncology, during the congress.The latest versions of RayStation (11A) and RayCare (5A) were released in May 2021. A new feature in the RayStation release is dose planning for Accuray’s CyberKnife® system for

Targovax invites to webcast presentation on Xtrainvestor

Oslo, Norway, 22 October 2021 – Targovax ASA (OSE: TRVX) has the pleasure of inviting investors, analysts and media to a live webcast presentation held by the company’s newly appointed CEO Erik Digman Wiklund on Monday 25 October at 14:00 CEST.Webcast URL: https://inqrate.com/xtravideos/targovax-trvx-presentasjon-25-oktober/ The presentation will be followed by a Q&A session moderated by analyst in DNB Markets Patrik Ling. Webcast viewers are welcome to submit questions in advance or during the presentation to info@xtrainvestor.com. ***

Invitation to presentation of Orexo´s Q3 Interim Report, on November 3 at 1 pm CET

Uppsala, Sweden – October 22, 2021 – As previously communicated Orexo will announce the Q3 2021 Interim Report, on November 3 at 8 am CET. The same day at 1 pm CET analysts, investors and media are invited to attend a presentation where Nikolaj Sørensen, CEO, Dennis Urbaniak, EVP Digital Therapeutics and Joseph DeFeo, CFO, will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to ir@orexo.com, no later than 11 am CET. Please view the instructions below on how to participate. Video link: https://tv.streamfabriken.com/orexo-q3-2021

BICO has been awarded the Swedish Government’s Award Exporter of the Year 2021

BICO has today been awarded the Swedish Government’s Award, Exporter of the Year 2021. The Award was presented by the Minister for Foreign Trade Anna Hallberg at a ceremony at the Ministry for Foreign Affairs in Stockholm with the attendance of HRH Prince Daniel. The novel Award is initiated by the Swedish government in effort to promote Swedish exports, by honoring companies that have made particularly meritorious efforts in inspiration and development. The motivation from the Government reads as follows: "BICO Group is a Swedish success story whose products are designed for the

poLight ASA - Invitation to presentation of Q3 2021 results

poLight ASA will release its Q3 2021 results on Friday 29 October 2021 at 7.00 am CEST. The quarterly report and presentation will be made available on the company's website www.polight.com and www.newsweb.no. CEO Øyvind Isaksen and CFO Alf Henning Bekkevik will present the company's results at 08:30 am CEST through live webcast. Please join the Q3 2021 results webcast by clicking here:https://channel.royalcast.com/landingpage/hegnarmedia/20211029_3/ 

TR-1: Standard form for notification of major holdings

TR-1: Standard form for notification of major holdings [][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(to besent to the relevantissuer and tothe FCA in MicrosoftWord format ifpossible)[i] 1a. Identity of the IOG PLCissuer or theunderlying issuer ofexisting sharesto which votingrights areattached[ii]:1b. Please indicateif the issuer isa non-UK issuer (please mark withan "X" ifappropriate)Non-UK issuer2. Reason for thenotification (pleasemark theappropriate box orboxes with an"X")An acquisition or

Registers of true owners of anonymous companies on track to become a requirement worldwide

The Financial Action Task Force’s proposed measures for strengthening the global standard a positive development in eliminating corporate secrecy Transparency International welcomes the proposed amendments  to the global standard on company ownership, released yesterday. The draft revisions, put forward by the Financial Action Task Force (FATF) following a three-day plenary, have the potential to significantly strengthen countries’ resistance to dirty money. Most notably, FATF is finally

Minesto recruits Communications Manager to further strengthen its marketing organisation

Minesto has appointed Cecilia Sernhage as Communications Manager and thus continues to strengthen the company's market organisation ahead of the commercial scale-up of Minesto's unique marine energy technology. Cecilia Sernhage has extensive experience in B2B communication with customers in global markets and provides Minesto with additional expertise and capacity to enhance and create new relationships with various stakeholders and partners.“We are very pleased to strengthen our commercial resources with Cecilia. Having worked for a long time with customer-focused B2B communication in a

HEXPOL Interim Report January - September 2021

JULY - SEPTEMBER 2021 · Sales increased by 23 percent and amounted to 4,108 MSEK (3,328). · EBIT increased by 86 percent to 1,105 MSEK (593). · EBIT-margin increased to 26.9 percent (17.8). · Adjusted EBIT (excl. non-recurring items) increased by 14 percent to 677 MSEK (593). · Adjusted EBIT-margin (excl. non-recurring items) amounted to 16.5 percent (17.8). · Profit after tax increased to 841 MSEK (426). · Earnings per share increased by 97 percent to 2.44 SEK (1.24). · Operating cash flow amounted to 412 MSEK (773). · Non-recurring items, before tax, amounted

Aker Carbon Capture and Elkem to test the world's first carbon capture pilot for smelters

Aker Carbon Capture and Elkem will test the world's first carbon capture plants for emissions from smelters in the process industry, and the first in the production of ferrosilicon. This week, the project received support from the CLIMIT-Demo program run by the Research Council of Norway and Gassnova, and will start up with Elkem Rana and SMA Mineral in Mo Industrial Park.Aker Carbon Capture will use its mobile test unit service, a unique offering with a fully functioning mobile carbon capture plant. The project is a collaboration between Mo Industripark AS, SINTEF, Elkem, Alcoa, Celsa,

Nordic Iron Ore AB extends the short-term loan facility

In February 2021, Nordic Iron Ore AB received a loan facility of SEK 10.5 million from the Company's principal owners Bengtssons Tidnings AB and Ludvika Holding AB and the company's board member Timo Lindborg via companies. The facility has now been extended by six months to run until the end of the first half of 2022. Summary of terms of the loan facility:  • Loan agreement totaling SEK 10.5 million  • The loans have an annual interest rate of 8 percent on the amount used.  • The loans run until 30 June 2022. Overall, the Board has made the assessment that the terms of the

TIE Kinetix Rebrands to Support Growing SaaS Business

TIE Kinetix , a leader in 100% supply chain digitalization, announced today that they have officially rebranded in order to support the continued growth of their cloud-based supply chain platform, FLOW Partner Automation. As a visual representation of the company’s narrowed focus, TIE Kinetix has introduced a new logo and website to better showcase their position as a leader in procure-to-pay and order-to-cash automation.Following the sale of the company’s demand generation business last year, TIE Kinetix immediately scaled down the product offering on

RNB Retail and Brands AB and Coala-Life AB enter into lock-up agreements with shareholders whose ownership amounts to 51 percent of the total number of shares

Due to RNB Retail and Brands AB's (“RNB” or “the Company”) acquisition of Coala-Life AB (“Coala Life”) through a non-cash issue, which was communicated by the Company on September 27, 2021, certain shareholders in Coala Life and in RNB has entered into so-called lock-up agreements with customary terms. According to the agreement, owners who will hold approximately 51 percent of the total number of shares in the Company after completion of the acquisition and the proposed debt conversions that the Company communicated on 15 October 2021, undertake not to sell or otherwise transfer shares in

Initiator Pharma A/S has been approved for listing on the Nasdaq First North Growth Market

Initiator Pharma A/S (“Initiator” or “the Company”) has today received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is October 25, 2021.Nasdaq Stockholm today announced that Initiator Pharma meets the listing requirements on Nasdaq First North Growth Market and the Company has received approval for admission to trading on Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is October 25, 2021. Initiator Pharma's share is currently listed on Spotlight Stock

There are no items matching the current filter
There are no more items matching the current filter
Back to top